Research programme: tuberculosis vaccine - GenexineAlternative Names: GX-140
Latest Information Update: 27 Jul 2010
At a glance
- Originator Genexine
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Tuberculosis
Most Recent Events
- 24 Oct 2007 Preclinical trials in Tuberculosis in South Korea (unspecified route)